Related Experiment Video
Updated: Sep 20, 2026
10:02
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
PTK/ZK (Novartis)
1Institute of Molecular Oncology, Department of Medical Oncology, Tumor Biology Center, Breisacher Strasse 117, 79106 Freiburg, Germany. drevs@tumorbio.uni-freiburg.de
Idrugs : the Investigational Drugs Journal
|August 15, 2003
Abstract:
PTK/ZK, a VEGF receptor tyrosine kinase inhibitor, is under development by Novartis AG and Schering AG as an inhibitor of angiogenesis for the potential treatment of various cancers.
Insights
PTK/ZK, a novel VEGF receptor tyrosine kinase inhibitor, is being developed to inhibit angiogenesis, offering potential new treatments for various cancers.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis.
- VEGF receptor tyrosine kinases play a critical role in regulating angiogenesis.
- Targeting angiogenesis is a promising strategy for cancer therapy.
Purpose of the Study:
- To describe the development of PTK/ZK, a novel inhibitor targeting VEGF receptor tyrosine kinases.
- To evaluate the potential of PTK/ZK as an anti-angiogenic agent for cancer treatment.
Main Methods:
- PTK/ZK is a small molecule inhibitor designed to block VEGF receptor tyrosine kinase activity.
- Development is being conducted by Novartis AG and Schering AG.
- The compound is under investigation for its anti-angiogenic properties.
Main Results:
- PTK/ZK functions as an inhibitor of VEGF receptor tyrosine kinase.
- The compound is being developed for its potential to inhibit angiogenesis.
- This inhibition is being explored for the treatment of various cancers.
Conclusions:
- PTK/ZK demonstrates potential as an anti-angiogenic therapeutic agent.
- Its development as a VEGF receptor tyrosine kinase inhibitor offers a new avenue for cancer treatment.
